keyword
MENU ▼
Read by QxMD icon Read
search

macular degeneration and p

keyword
https://www.readbyqxmd.com/read/28107458/neuropilin-1-involvement-in-choroidal-and-retinal-neovascularisation
#1
Patricia Fernández-Robredo, Senthil Selvam, Michael B Powner, Dawn A Sim, Marcus Fruttiger
PURPOSE: Inhibiting VEGF is the gold standard treatment for neovascular age-related macular degeneration (AMD). It is also effective in preventing retinal oedema and neovascularisation (NV) in diabetic retinopathy (DR) and retinal vein occlusions (RVO). Neuropilin 1 (Nrp1) is a co-receptor for VEGF and many other growth factors, and therefore a possible alternative drug target in intra ocular neovascular disease. Here we assessed choroidal and retinal NV in an inducible, endothelial specific knock out model for Nrp1...
2017: PloS One
https://www.readbyqxmd.com/read/28105123/effect-of-anti-vegf-drugs-combined-with-photodynamic-therapy-in-the-treatment-of-age-related-macular-degeneration
#2
Yi Dong, Guangming Wan, Panshi Yan, Yue Chen, Wenzhan Wang, Guanghua Peng
We analyzed the effects of anti-vascular endothelial growth factor (VEGF) drugs combined with photodynamic therapy (PDT) in the treatment of age-related macular degeneration (AMD). Ninety-six cases (192 eyes) of AMD were included in this study and randomly divided into the observation group and control group (n=48 cases per group). The control group was administered the treatment of Lucentis intravitreal injection alone and the observation group was administered Lucentis combined with PDT. The therapeutic effects were compared...
December 2016: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28102456/efficacy-and-safety-of-a-fixed-bimonthly-ranibizumab-treatment-regimen-in-eyes-with-neovascular-age-related-macular-degeneration-results-from-the-rabimo-trial
#3
Nicolas Feltgen, Thomas Bertelmann, Mirko Bretag, Sebastian Pfeiffer, Reinhard Hilgers, Josep Callizo, Lena Goldammer, Sebastian Bemme, Hans Hoerauf
PURPOSE: To evaluate prospectively the efficacy and safety of a fixed bimonthly ranibizumab treatment regimen (RABIMO) in eyes with neovascular age-related macular degeneration (nAMD) and to compare these results with a pro re nata (PRN) treatment scheme. METHODS: This was a 12-month, phase IV, single center, randomised, non-inferiority study. Following three initial monthly injections, patients were randomised to receive either ranibizumab bimonthly (RABIMO group) or ranibizumab PRN (PRN group) (n = 20 each)...
January 19, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28096652/erratum-macular-morphology-and-response-to-ranibizumab-treatment-in-patients-with-wet-age-related-macular-degeneration-corrigendum
#4
(no author information available yet)
[This corrects the article on p. 1117 in vol. 10, PMID: 27366051.].
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28095127/association-of-the-dna-repair-smug1-rs3087404-polymorphism-and-its-interaction-with-high-sensitivity-c-reactive-protein-for-age-related-macular-degeneration-in-iranian-patients
#5
Mortaza Bonyadi, Faride Mehdizadeh, Mohammad Hossein Jabbarpoor Bonyadi, Masoud Soheilian, Alireza Javadzadeh, Mehdi Yaseri
BACKGROUND: Age-related macular degeneration (AMD) is a complex disease and recently the role of DNA repairing genes in its susceptibility has been studied. It has been hypothesized that polymorphism in DNA repair system genes reduce the capacity to repair DNA damages which may lead to a greater susceptibility to AMD. C-reactive protein (CRP) production is shown to enhance inflammatory processes by increasing oxidative stress and inducing DNA damage. We planned to evaluate the possible association of SMUG1 variants and their possible interaction with high sensitivity CRP levels in AMD...
January 17, 2017: Ophthalmic Genetics
https://www.readbyqxmd.com/read/28095095/joint-association-of-complement-component-3-and-cc-cytokine-ligand2-ccl2-or-complement-component-3-and-cfh-polymorphisms-in-age-related-macular-degeneration
#6
Mortaza Bonyadi, Mohammad Hossein Jabbarpoor Bonyadi, Mehdi Yaseri, Tahereh Mohammadian, Nikou Fotouhi, Alireza Javadzadeh, Masoud Soheilian
BACKGROUND: To determine the joint effect of complement component 3(C3 R102G) with CC-cytokine ligand2 (CCL2-2518) or complement factor H (CFH) Y402H polymorphisms on advanced age-related macular degeneration (AMD). METHODS: In this case-control study, 233 patients with advanced AMD and 159 unrelated healthy controls enrolled for evaluation. Selected polymorphisms were determined by polymerase chain reaction and restriction fragment length polymorphism. RESULTS: A combination of AA CCL2 (rs1024611) and GG C3 (R102G) genotypes resulted in a super-additivity of the risks: OR = 10...
January 17, 2017: Ophthalmic Genetics
https://www.readbyqxmd.com/read/28095090/associations-between-rs4244285-and-rs762551-gene-polymorphisms-and-age-related-macular-degeneration
#7
Neringa Stasiukonyte, Rasa Liutkeviciene, Alvita Vilkeviciute, Mantas Banevicius, Loresa Kriauciuniene
BACKGROUND: Age-related macular degeneration is the leading cause of blindness in elderly individuals in developed countries. The etiology and pathophysiology of age-related macular degeneration have not been elucidated yet. Knowing that the main pathological change of age-related macular degeneration is formation of drusen containing about 40% of lipids, there have been attempts to find associations between age-related macular degeneration and genes controlling lipid metabolism. PURPOSE: To determine the frequency of CYP2C19 (G681A) Rs4244285 and CYP1A2 (-163C>A) Rs762551 genotypes in patients with age-related macular degeneration...
January 17, 2017: Ophthalmic Genetics
https://www.readbyqxmd.com/read/28092343/natural-course-of-patients-discontinuing-treatment-for-age-related-macular-degeneration-and-factors-associated-with-visual-prognosis
#8
Jae Hui Kim, Young Suk Chang, Jong Woo Kim
PURPOSE: To evaluate the 24-month natural course of visual changes in patients discontinuing treatment despite persistent or recurrent fluid and factors predictive of visual prognosis. METHODS: This retrospective, observational study included 35 patients (35 eyes) who initially received anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration (AMD), but discontinued treatment despite persistent or recurrent fluid. The best-corrected visual acuity (BCVA) at treatment discontinuation was determined and compared with the 24-month BCVA, which was then compared between polypoidal choroidal vasculopathy and other neovascular age-related macular degeneration subtypes...
January 13, 2017: Retina
https://www.readbyqxmd.com/read/28089680/peripheral-retinal-changes-associated-with%C3%A2-age-related-macular-degeneration-in%C3%A2-the-age-related-eye-disease-study-2-age-related-eye-disease-study-2-report-number-12-by-the%C3%A2-age-related-eye-disease-study-2-optos-peripheral-retina-opera-study-research-group
#9
Amitha Domalpally, Traci E Clemons, Ronald P Danis, SriniVas R Sadda, Catherine A Cukras, Cynthia A Toth, Thomas R Friberg, Emily Y Chew
PURPOSE: To compare rates of peripheral retinal changes in Age-Related Eye Disease Study 2 (AREDS2) participants with at least intermediate age-related macular degeneration (AMD) with control subjects without intermediate age-related changes (large drusen). DESIGN: Cross-sectional evaluation of clinic-based patients enrolled in AREDS2 and a prospective study. PARTICIPANTS: Participants from prospective studies. METHODS: The 200° pseudocolor and fundus autofluorescence (FAF) images were captured on the Optos 200 Tx Ultrawide-field device (Optos, Dunfermline, Scotland) by centering on the fovea and then steering superiorly and inferiorly...
January 12, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28079023/incidence-and-growth-of-geographic-atrophy-during-5-years-of-comparison-of-age-related-macular-degeneration-treatments-trials
#10
Juan E Grunwald, Maxwell Pistilli, Ebenezer Daniel, Gui-Shuang Ying, Wei Pan, Glenn J Jaffe, Cynthia A Toth, Stephanie A Hagstrom, Maureen G Maguire, Daniel F Martin
PURPOSE: To estimate the incidence, size, and growth rate of geographic atrophy (GA) during 5 years of follow-up among participants in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). DESIGN: Cohort within a clinical trial. PARTICIPANTS: Participants included in CATT. METHODS: A total of 1185 CATT participants were randomly assigned to ranibizumab or bevacizumab treatment and to 3 treatment regimens...
January 2017: Ophthalmology
https://www.readbyqxmd.com/read/28076566/efficacy-of-aflibercept-on-exudative-age-related-macular-degeneration-in-patients-exhibiting-complete-ranibizumab-resistance-and-tachyphylaxis
#11
Gokcen Gokce, Ali Hakan Durukan, Mehmet Talay Koylu, Murat Kucukevcilioglu
Purpose: The present study compared the efficacy of aflibercept for neovascular age-related macular degeneration (NV-AMD) in patients with complete ranibizumab resistance and tachyphylaxis. Methods: Forty-four eyes of 38 neovascular age-related macular degeneration patients were evaluated. Eyes were divided into a complete resistance group (n=23 eyes) and tachyphylaxis group (n=21 eyes). Results: After three injections, eight (38.1%) patients in the tachyphylaxis group and nine (39...
November 2016: Arquivos Brasileiros de Oftalmologia
https://www.readbyqxmd.com/read/28060360/short-term-effects-of-intravitreal-ranibizumab-and-bevacizumab-administration-on-24-h-ambulatory-blood-pressure-monitoring-recordings-in-normotensive-patients-with-age-related-macular-degeneration
#12
A Sengul, R Rasier, C Ciftci, O Artunay, A Kockar, H Bahcecioglu, E Yuzbasioglu
PurposeTo evaluate effects of intravitreal ranibizumab and bevacizumab administration on ambulatory blood pressure monitoring (ABPM) recordings in normotensive patients with age-related macular degeneration (AMD).Patients and methodsA total of 72 patients (mean age: 61.8(6.2) years, 52.8% were females) diagnosed with AMD were included in this study as divided into ranibizumab (n=34) and bevacizumab (n=38) treatment groups. Twenty-four hour, nighttime, and daytime ABMP values for systolic and diastolic BP were recorded in study groups before and after the third intravitreal injection of ranibizumab or bevacizumab...
January 6, 2017: Eye
https://www.readbyqxmd.com/read/28060148/short-term-safety-of-2-mg-intravitreal-ziv-aflibercept
#13
Jay Chhablani, Chintan Jethalal Dedhia, Hari K Peguda, Michael Stewart
PURPOSE: To evaluate the safety of single intravitreal 2 mg ziv-aflibercept (0.08 mL) injections for the treatment of choroidal neovascular membranes (CNVM). METHODS: Eyes with choroidal neovascular membranes because of several conditions each received single intravitreal injections of 2 mg ziv-aflibercept (0.08 mL). Comprehensive ophthalmic examinations and detailed systemic evaluations were performed at baseline and Days 1, 7, and 30 after injections. Standard electroretinography was performed at baseline and Day 30...
January 2, 2017: Retina
https://www.readbyqxmd.com/read/28057649/choroid-morphometric-analysis-in-non-neovascular-age-related-macular-degeneration-by-means-of-optical-coherence-tomography-angiography
#14
Maria Vittoria Cicinelli, Alessandro Rabiolo, Alessandro Marchese, Luigi de Vitis, Adriano Carnevali, Lea Querques, Francesco Bandello, Giuseppe Querques
AIMS: To describe the vascular changes in patients affected by non-neovascular age-related macular degeneration (AMD), featuring reticular pseudodrusen (RPD), drusen, or both RPD and drusen by means of optical coherence tomography angiography (OCT-A). METHODS: Cross-sectional observational case series. Patients with non-neovascular AMD presenting at the Medical Retina Service of the Department of Ophthalmology, University Vita-Salute San Raffaele in Milan were recruited...
January 5, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28053502/neovascular-age-related-macular-degeneration-without-drusen-in-the-fellow-eye-clinical-spectrum-and-therapeutic-outcome
#15
Wing H Chung, Elon H C van Dijk, Danial Mohabati, Greet Dijkman, Suzanne Yzer, Eiko K de Jong, Sascha Fauser, Reinier O Schlingemann, Carel B Hoyng, Camiel J F Boon
PURPOSE: To investigate the clinical characteristics and therapeutic outcome of patients with neovascular age-related macular degeneration (nAMD) in 1 eye, without drusen in the fellow eye. PATIENTS AND METHODS: Medical records of 381 patients were analyzed to identify the cases. The main outcomes included Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) and change in central retinal thickness (CRT). These parameters were reviewed at baseline, first follow-up visit, and after 6, 12, and 24 months...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28045789/imaging-and-measurement-of-the-preretinal-space-in-vitreomacular-adhesion-and-vitreomacular-traction-by-a-new-spectral-domain-optical-coherence-tomography-analysis
#16
Marcin Stopa, Elżbieta Marciniak, Piotr Rakowicz, Agnieszka Stankiewicz, Tomasz Marciniak, Adam Dąbrowski
PURPOSE: To evaluate a new method for volumetric imaging of the preretinal space (also known as the subhyaloid, subcortical, or retrocortical space) and investigate differences in preretinal space volume in vitreomacular adhesion (VMA) and vitreomacular traction (VMT). METHODS: Nine patients with VMA and 13 with VMT were prospectively evaluated. Automatic inner limiting membrane line segmentation, which exploits graph search theory implementation, and posterior cortical vitreous line segmentation were performed on 141 horizontal spectral domain optical coherence tomography B-scans per patient...
December 30, 2016: Retina
https://www.readbyqxmd.com/read/28029445/dual-antagonism-of-pdgf-and-vegf-in-neovascular-age-related-macular-degeneration-a-phase-iib-multicenter-randomized-controlled-trial
#17
Glenn J Jaffe, Thomas A Ciulla, Antonio P Ciardella, Francois Devin, Pravin U Dugel, Chiara M Eandi, Harvey Masonson, Jordi Monés, Joel A Pearlman, Maddalena Quaranta-El Maftouhi, Federico Ricci, Keith Westby, Samir C Patel
PURPOSE: To assess the safety and efficacy of E10030 (Fovista; Ophthotech, New York, NY), a platelet-derived growth factor (PDGF) antagonist, administered in combination with the anti-vascular endothelial growth factor (VEGF) agent ranibizumab (Lucentis; Roche, Basel, Switzerland) compared with ranibizumab monotherapy in patients with neovascular age-related macular degeneration (nAMD). DESIGN: Phase IIb global, multicenter, randomized, prospective, double-masked, controlled superiority trial...
October 28, 2016: Ophthalmology
https://www.readbyqxmd.com/read/28029444/associations-between-serum-vitamin-d-and-genetic-variants-in-vitamin-d-pathways-and-age-related-macular-degeneration-in-the-european-eye-study
#18
Gareth J McKay, Ian S Young, Ann McGinty, Graham C G Bentham, Usha Chakravarthy, Mati Rahu, Johan Seland, Gisele Soubrane, Laura Tomazzoli, Fotis Topouzis, Jesus Vioque, Paulus T V M de Jong, Astrid E Fletcher
PURPOSE: To study associations between early and late age-related macular degeneration (AMD) and neovascular AMD (nvAMD) with serum 25-hydroxy vitamin D (25(OH)D) and genetic variants in vitamin D pathway genes. DESIGN: Population-based, cross-sectional study in a random sample aged 65 years or older from 7 European countries. PARTICIPANTS: Of 4753 participants, 4496 (2028 men and 2468 women), with a mean age of 73 years, provided a blood sample; 2137 had no signs of AMD, 2209 had early AMD, and 150 had late AMD, of whom 104 had nvAMD...
October 28, 2016: Ophthalmology
https://www.readbyqxmd.com/read/28027551/the-risk-of-macular-degeneration-development-in-persons-antenatally-irradiated-as-a-result-of-chornobyl-npp-accident
#19
T F Babenko, P A Fedirko, R Y Dorichevska, N V Denysenko, L A Samoteikina, O P Tyshchenko
OBJECTIVE: Assess the risk of macular degeneration development in persons exposed in utero as a result of Chornobyl NPP accident. MATERIALS AND METHODS: The object of the study was the state of the macular area of the retina of 84 individuals exposed in utero as a result of the Chornobyl disaster. They were surveyed at the age of 14-30. The results of stan dardized ophthalmic examinations conducted between 2000 and 2016 were used. The control group consisted of 165 persons who have not undergone prenatal exposure and were examined at the same age as the core group...
December 2016: Problemy Radiat︠s︡iĭnoï Medyt︠s︡yny Ta Radiobiolohiï
https://www.readbyqxmd.com/read/28027382/training-eye-movements-for-visual-search-in-individuals-with-macular-degeneration
#20
Christian P Janssen, Preeti Verghese
We report a method to train individuals with central field loss due to macular degeneration to improve the efficiency of visual search. Our method requires participants to make a same/different judgment on two simple silhouettes. One silhouette is presented in an area that falls within the binocular scotoma while they are fixating the center of the screen with their preferred retinal locus (PRL); the other silhouette is presented diametrically opposite within the intact visual field. Over the course of 480 trials (approximately 6 hr), we gradually reduced the amount of time that participants have to make a saccade and judge the similarity of stimuli...
December 1, 2016: Journal of Vision
keyword
keyword
102809
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"